Caladrius Biosciences, Inc. (LSTA) Misses Q3 EPS by 638c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LSTA Hot Sheet
Join SI Premium – FREE
Caladrius Biosciences, Inc. (NASDAQ: LSTA) reported Q3 EPS of ($7.88), $6.38 worse than the analyst estimate of ($1.50).
For earnings history and earnings-related data on Caladrius Biosciences, Inc. (LSTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veracyte (VCYT) Tops Q3 EPS by 10c ; Offers Guidance
- Eversource Energy (ES) Tops Q3 EPS by 18c; offers guidance
- Progyny (PGNY) Tops Q3 EPS by 21c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
